Cocco Eleonora, Fadda Paola
Dpt. Medical Science and Public Health, University of Cagliari, Italy; Multiple Sclerosis Center, ASSL Cagliari, ATS Sardegna, Italy.
Dpt. of Biomedical Science, University of Cagliari, Italy.
Exp Neurol. 2022 Jan;347:113906. doi: 10.1016/j.expneurol.2021.113906. Epub 2021 Oct 26.
Multiple sclerosis (MS) is a complex disorder characterized by a broad spectrum of symptoms that evolve throughout the disease. Symptoms can be categorized as visible and invisible based on external sight recognition. However, although others poorly recognize it, invisible symptoms such as mood dysfunction, neuropathic pain, or fatigue can significantly affect activities of daily living and the quality of life of people with MS (PwMS). PwMS frequently complain of fatigue, which has physical or cognitive manifestations. Fatigue in MS does not improve or resolve with rest, and it is disproportionate with respect to the exerted effort. Fatigue management in MS is challenging, and a few pharmacological approaches have been successfully proposed. Among them, the drug modafinil has attracted attention because of its properties as a synthetic psychoactive drug. In this review, we focus on the evidence available to date, supporting the use of modafinil in MS fatigue. However, despite the availability of some trials evaluating the effects of modafinil on fatigue, their contrasting results failed to support its usefulness in fatigue management in MS.
多发性硬化症(MS)是一种复杂的疾病,其特征是在整个病程中会出现广泛的症状。根据外部视觉识别,症状可分为可见和不可见两类。然而,尽管其他人很难识别,但诸如情绪功能障碍、神经性疼痛或疲劳等不可见症状会显著影响多发性硬化症患者(PwMS)的日常生活活动和生活质量。PwMS经常抱怨疲劳,疲劳有身体或认知方面的表现。MS中的疲劳不会通过休息得到改善或缓解,并且与所付出的努力不成比例。MS中的疲劳管理具有挑战性,已经成功提出了一些药物治疗方法。其中,莫达非尼因其作为合成精神活性药物的特性而受到关注。在这篇综述中,我们关注迄今为止支持在MS疲劳中使用莫达非尼的现有证据。然而,尽管有一些试验评估了莫达非尼对疲劳的影响,但它们相互矛盾的结果未能支持其在MS疲劳管理中的有效性。